Biophytis SA Advances Obesity Treatment with BIO101

Biophytis SA (FR:ALBPS) has released an update.

Biophytis SA showcased its OBA program using BIO101 at the SCWD congress, highlighting promising results in reducing muscle loss in obese patients. The company plans to initiate a phase 2 study in 2025 to further investigate BIO101’s efficacy and safety, with results expected by the end of the year. This development is part of Biophytis’s strategic focus on advancing treatments for age-related diseases.

For further insights into FR:ALBPS stock, check out TipRanks’ Stock Analysis page.